The Pertinence of the Amyloid Hypothesis Questioned by Landmark Cochrane Review

The scientific community’s long-held focus on the amyloid hypothesis as the primary driver of Alzheimer’s disease is facing significant scrutiny following a comprehensive meta-analysis published by Cochrane. The review, which synthesized data from 17 randomized controlled trials, concludes that while monoclonal antibodies targeting amyloid-beta peptides can effectively clear these protein deposits from the brains of patients with mild cognitive impairment (MCI) or mild Alzheimer’s dementia, this biological effect does not translate into clinically meaningful benefits for patients. This finding, published on April 16, 2026, in the Cochrane Library, casts a long shadow over a therapeutic strategy that has dominated Alzheimer’s research for decades and represents a pivotal moment in the quest for effective treatments.

The debate surrounding the net clinical benefit of these amyloid-targeting therapies has been intensifying within the scientific sphere, with regulatory bodies adopting divergent stances. In this landscape, the results of the Cochrane review are deemed crucial for informing clinical decision-making. Francesco Nonino, a neurologist and epidemiologist at IRCCS Istituto delle Scienze Neurologiche in Bologna, Italy, and his colleagues, led the extensive meta-analysis, aiming to provide a definitive assessment of the current therapeutic landscape.

Background: The Amyloid Hypothesis and its Promise

For over three decades, the amyloid hypothesis has been the dominant paradigm in Alzheimer’s disease research. This theory posits that the accumulation of amyloid-beta plaques in the brain is the primary pathological event that triggers a cascade of neurodegenerative processes, ultimately leading to cognitive decline and dementia. This hypothesis has guided the development of numerous therapeutic strategies, with a significant focus on agents designed to clear these amyloid deposits.

The advent of monoclonal antibodies that specifically target amyloid-beta peptides represented a significant breakthrough, offering the potential to directly address the hypothesized root cause of the disease. These therapies work by binding to amyloid-beta, marking it for removal by the immune system, or by preventing its aggregation into toxic plaques. Early studies and preclinical data had shown promising results in reducing amyloid burden in the brain. However, the transition from reducing amyloid to demonstrating tangible clinical improvement for patients has proven to be a formidable challenge.

Chronology of Events and Regulatory Divergence

The journey of amyloid-targeting therapies has been marked by both excitement and disappointment. The development of drugs like aducanumab, lecanemab, and donanemab has followed a winding path through clinical trials and regulatory reviews.

• Early Research: Decades of research focused on the amyloid cascade hypothesis, leading to the development of various experimental treatments.
• Aducanumab Approval (2021): The U.S. Food and Drug Administration (FDA) granted accelerated approval to aducanumab (Aduhelm) based on its ability to reduce amyloid plaques, despite mixed results in clinical trials regarding cognitive benefits. This decision was highly controversial, sparking debate about the criteria for drug approval in Alzheimer’s.
• Lecanemab Approval (2023): Lecanemab (Leqembi), developed by Eisai and Biogen, received full FDA approval after demonstrating a statistically significant, albeit modest, slowing of cognitive decline in patients with early-stage Alzheimer’s. This was seen as a validation of the amyloid-targeting approach.
• Donanemab Trials and Review: Eli Lilly’s donanemab also showed promise in reducing amyloid and slowing cognitive decline in clinical trials, leading to ongoing regulatory review processes.
• European Regulatory Decisions (2025-2026): In stark contrast to the U.S. approach, European regulatory bodies have been more cautious. In France, for instance, the Haute Autorité de Santé (HAS) initially refused early access to both lecanemab and donanemab. Lecanemab was subsequently denied a favorable assessment for medical reimbursement in September 2025, with the HAS deeming its medical benefit insufficient. Similarly, donanemab faced a negative opinion in late March 2026.

The Cochrane review, published in April 2026, arrives at a critical juncture, potentially influencing future regulatory decisions and clinical practice.

Methodology of the Cochrane Review

The researchers conducted a meta-analysis of randomized controlled trials (RCTs) that were published up to August 2025. The inclusion criteria stipulated that these trials must have a follow-up period of at least 12 months and compare a monoclonal antibody targeting amyloid-beta against a placebo or no treatment in patients diagnosed with mild cognitive impairment (MCI) or mild Alzheimer’s dementia.

A total of 17 studies were included in the analysis. Notably, all these studies were funded by the pharmaceutical industry, which is a common characteristic of drug development research. These studies evaluated seven different monoclonal antibodies:

• Aducanumab (3 studies)
• Bapineuzumab (4 studies)
• Crenezumab (2 studies)
• Donanemab (1 study)
• Gantenerumab (4 studies)
• Lecanemab (1 study)
• Solanezumab (2 studies)

These trials collectively involved 20,342 participants. The average age of participants ranged between 70 and 74 years across the studies, and they had experienced cognitive impairments for an average duration of 17 to 52 months. The researchers focused their analysis on outcomes observed at the 18-month follow-up mark.

Key Findings: The Disconnect Between Amyloid Clearance and Clinical Benefit

The core finding of the Cochrane review is the stark disconnect between the biological effect of amyloid clearance and actual patient benefit. The analysis revealed that the impact of these monoclonal antibodies on cognitive functions, as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and on the severity of dementia, assessed by the Clinical Dementia Rating Sum of Boxes (CDR-SB), was either "absent or trivial."

The magnitude of the observed effects was consistently "well below the thresholds required to consider the observed difference clinically important," the researchers stated in a Cochrane press release. This implies that while statistical significance might have been achieved in some individual trials, the effect size was too small to be meaningful in the daily lives of patients or their caregivers.

Furthermore, the review examined the impact on functional capacities. While there was a "slight" improvement noted on certain scales such as the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-iADL) and the ADCS-ADL-MCI, no significant improvement was observed on the ADCS-ADL scale, which measures daily living activities. This mixed picture on functional outcomes further underscores the limited clinical utility.

Safety Profile: ARIA-E and the Absence of Major Adverse Events

While the clinical benefits remained elusive, the review did highlight a concerning safety signal. The researchers observed a slight increase in the risk of amyloid-related imaging abnormalities, specifically cerebral edema (ARIA-E). These abnormalities, often associated with amyloid plaque disruption, were most frequently observed without symptomatic manifestation. However, the study found no significant difference in the incidence of serious adverse events or mortality when compared to the placebo group. This suggests that while the treatments may not be significantly increasing the risk of life-threatening complications, the observed ARIA-E warrants careful monitoring.

Implications for Future Alzheimer’s Research and Treatment

The implications of this comprehensive meta-analysis are profound and far-reaching. "The data unfortunately show that these treatments do not really change much for patients," commented Francesco Nonino in the press release. He elaborated that it is not uncommon for results that are statistically significant in early trials to not translate into clinical relevance.

The conclusion drawn by the researchers is unequivocal: "The ability to clear amyloid-beta deposits from the brain does not appear to be associated with clinically relevant effects in individuals with mild cognitive impairment or mild dementia due to Alzheimer’s disease."

Based on the available evidence up to this point, the researchers express skepticism that future clinical studies focusing solely on amyloid-beta peptide clearance will yield clear benefits for Alzheimer’s patients. They strongly recommend that research efforts be redirected towards exploring alternative mechanisms of action. This call to diversify research strategies signals a potential paradigm shift away from the amyloid-centric approach that has dominated the field for so long.

Broader Impact and Expert Reactions

The findings of the Cochrane review are expected to significantly influence ongoing research, drug development, and clinical practice.

• Research Funding and Direction: Pharmaceutical companies and funding bodies may re-evaluate their investment in amyloid-targeting therapies and shift resources towards other promising avenues, such as tau pathology, neuroinflammation, or synaptic dysfunction.
• Clinical Practice Guidelines: Healthcare providers and professional organizations will need to consider these findings when making treatment recommendations. The cost and potential side effects of amyloid-clearing therapies, coupled with their lack of demonstrable clinical benefit, could lead to their limited use or discontinuation in many settings.
• Patient and Caregiver Expectations: The review may temper the expectations of patients and their families who have been hoping for a breakthrough treatment. Clearer communication about the limitations of current therapies will be essential.
• Regulatory Scrutiny: The review could lead to increased scrutiny from regulatory agencies worldwide, potentially impacting the approval pathways for new amyloid-targeting drugs.

While the review focuses on the current generation of amyloid-clearing antibodies, it is important to note that the scientific understanding of Alzheimer’s disease is constantly evolving. Some researchers may argue that the specific targets or the timing of intervention within the amyloid cascade might still hold potential. However, the overwhelming evidence presented by this meta-analysis suggests that the amyloid hypothesis, in its current form, may not be the sole or primary answer to Alzheimer’s disease.

The path forward for Alzheimer’s research now appears to demand a more multifaceted approach, exploring the complex interplay of various pathological processes that contribute to this devastating neurodegenerative condition. The Cochrane review serves as a critical, data-driven inflection point, urging the scientific community to broaden its horizons and pursue novel therapeutic strategies with renewed urgency.

This article is based on information published in APMnews on April 16, 2026.